Neptune Technologies & Bioressources Inc. Appoints V.P. Sales & Marketing
Thursday, April 20 2006

Neptune Technologies & Bioressources Inc. Appoints V.P. Sales & Marketing

Laval Quebec CANADA, April 20, 2006 – Neptune Technologies and Bioressources (NTB: TSX-V) «Neptune » is pleased to announce that Mr. Donald Allard has joined Neptune as the Vice President, Sales and Marketing. Mr. Allard will be involved in all aspects of the sales process and marketing, including business development, branding, customer relations, and promotion.

Mr. Allard brings more than 15 years experience in sales and marketing of pharmaceutical products in some of the most prevalent diseases in the western world such as, obesity, diabetes and hyperlipidemia. Mr. Allard is trained as a hospital pharmacist and has six years of clinical practice in a university hospital.

“Mr. Allard has the proven experience and the credentials to lead our sales efforts to levels never before achieved. I am confident that Mr. Allard’s admirable experience will be an invaluable asset in this next stage of our growth,” says Mr. Henri Harland, President & CEO at Neptune.

“Neptune is at an exciting time in its development," said Mr. Donald Allard. "With a world-class natural product that has proven health benefits, strong partnerships and a solid management team, Neptune is well positioned for tremendous growth."

About Neptune Technologies & Bioressources Inc. https://www.neptunebiotech.com/
Neptune Technologies & Bioressources Inc. develops high value added nutritional products from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract™). Using an exclusive process, Neptune Technologies & Bioressources Inc. is well positioned in the $182 billion global nutrition market (Nutrition Business Journal, Oct/Nov 2004) of health and wellness concepts.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the adequacy or accuracy of this press release.
Neptune Technologies and Acasti Pharma Contact:
Neptune Technologies & Bioressources Inc.
Acasti Pharma Inc.
Toni Rinow, Ph.D., MBA
Corporate Development & Investor Relations
(450) 687-2262
This e-mail address is being protected from spambots, you need JavaScript enabled to view it
# # #
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.
 

We communicate

NTB (TSX) CAN$ 1.93 +0.03
NEPT (NASDAQ) US$ 1.898 +0.068
 

press releases

Investor Relations Contact NEPTUNE TECHNOLOGIES & BIORESSOURCES